## Physician Publications and Presentations Brain and Spine • Newton

## **Publications:**

Wheeler LA, Manzanera AG, Bell S, Cavaliere R, McGregor J, Lo S, Grecula J, **Newton HB**, et al; "Phase II Multicenter Study of Gene Mediated Cytotoxic Immunotherapy as Adjuvant to Surgical Resection for Newly Diagnosed Malignant Glioma"; Neuro Oncology, 2016; Feb 2. Pii: now002. [Epub ahead of print].

**Newton HB; "**Handbook of Neuro-Oncology Neuro-Imaging, 2<sup>nd</sup> Edition"; Elsevier Medical Publishers/ Academic Press, 2016.

In Handbook of Neuro-Oncology Neuro-Imaging, 2<sup>nd</sup> Edition. **Newton HB** (Ed.). Elsevier Medical Publishers/ Academic Press. **Newton HB**: Overview of brain tumor epidemiology (1:3-8); Overview of pathology and treatment of primary brain tumors (2:9-22); Overview of pathology and treatment of metastatic brain tumors (3:23-34); Overview of spinal cord tumor epidemiology (4:35-39); Overview of pathology and treatment of spinal cord tumors (5:41-54); Overview of pathology and treatment of intramedullary spinal cord metastases (6:55-58). **Newton HB**, Slone HW, Bourekas EC: Primary central nervous system lymphoma. (41:471-482); Bourekas EC, **Newton HB**, Slone HW: Chordomas and other skull base tumors (49:603-612); **Newton HB**, Slone HW, Bourekas EC: Papillary glioneuronal tumors. (51:635-642); Sun, Y, **Newton HB**: Neuroimaging of brain tumors in animal models of central nervous system cancer. (36:395-408).

## **Lectures and Presentations**

**Newton HB,** Kettering Medical Center/Kettering Health Network, Neuroscience Symposium 2016, Kettering, OH, 1/20/2016: "Neuro-Oncology Update on Brain Tumor Patient Care: Genomics, Optune, and Immuno-Oncology."

**Newton HB,** Upper Midwest NF-2 Conference, Columbus, OH; 10/07/16: "The use of Bevacizumab (Avastin) for NF-2-related Schwannomas: Update."

**Newton HB,** Chair: Live from Scottsdale: "FAQ's and Best Practices in the Management of Glioblastoma," SNO Meeting 2016, Scottsdale, AZ; 11/19/2016.

**Newton HB,** GBM Case 2 Presentation: Live from Scottsdale: "FAQ's and Best Practices in the Management of Glioblastoma," SNO Meeting 2016, Scottsdale, AZ; 11/19/2016.

February 20th, 2013: Round table discussion regarding gene expression profiling and G-Cimp evaluation for gliomas (Castlebiosciences). Del Frisco's, Orlando, Florida.

February 23rd, 2013: Neuro-Oncology discussion at Sarah Cannon Research Institute Annual Scientific Meeting. Nashville Downtown Hilton hotel, TN. Presented at the Genentech Advisory Board Meeting, San Francisco, Intercontinental Hotel, March 2013.

March 9th, 2013: Malignant Gliomas: An Update. Florida Brain Tumor Association(FBTA) Annual meeting. West Palm Beach, Florida.

March 9th, 2013: Mock Tumor Board Presentation. Florida Brain Tumor Association(FBTA) Annual meeting. West Palm Beach, Florida.

Presented Gliadel to the Mexican FDA, April 2013

High Grade Glioma Management Presentation and Discussion, Gliadel Advisory Board Meeting, July 19th and the 20th, Chicago, IL.

January 12<sup>th</sup>, 2012: Current Concepts in Glioblastoma Management: Oncology Grand Rounds, Tampa, Florida.

March 14<sup>th</sup>, 2012: Malignant Glioma Management: Oncology Lecture, Café Margeaux, Cocoa Beach, Fl

March 28<sup>th</sup>, 2012: Leptomeningeal Metastases, A Review, Oncology Noon Rounds, South Carolina Oncology Associates, Columbia, SC.

June 20<sup>th</sup>, 2012: Current Concepts of Leptomeningeal metastases. Oncology Grand Rounds, Charlotte, NC.

November 16<sup>th</sup>, 2012: Molecular genetic testing and therapeutic decisions in Glioblastoma. Society for Neuro-Oncology (SNO) Annual Meeting. Washington DC.

December 7<sup>th</sup>, 2012: Antiangiogenesis and Glioblastoma. Intercontinental Hotel, San Francisco, CA.

December 18<sup>th</sup>, 2012: RECOTHROM and immune mediated coagulopathy. Ruth Chris Steak House, Fort Lauderdale, Fl.